Compare · PCG vs VIVO
PCG vs VIVO
Side-by-side comparison of Pacific Gas & Electric Co. (PCG) and VivoPower PLC (VIVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PCG and VIVO operate in Power Generation (Utilities), so they compete in similar markets.
- PCG is the larger of the two at $44.43B, about 338.9x VIVO ($131.1M).
- Over the past year, PCG is up 13.2% and VIVO is down 27.6% - PCG leads by 40.8 points.
- PCG has been more active in the news (20 items in the past 4 weeks vs 3 for VIVO).
- PCG has more recent analyst coverage (25 ratings vs 3 for VIVO).
Pacific Gas & Electric Co.
PG&E Corporation, through its subsidiary, Pacific Gas and Electric Company, engages in the sale and delivery of electricity and natural gas to customers in northern and central California, the United States. It generates electricity using nuclear, hydroelectric, fossil fuel-fired, fuel cell, and photovoltaic sources. As of December 31, 2020, the company owns and operates approximately 18,000 circuit miles of interconnected transmission lines, 35 electric transmission substations, approximately 108,000 circuit miles of distribution lines, 68 transmission switching substations, and 758 distribution substations; and natural gas transmission, storage, and distribution system consisting of approximately 43,500 miles of distribution pipelines, approximately 6,300 miles of backbone and local transmission pipelines, and various storage facilities. It serves residential, commercial, industrial, and agricultural customers, as well as natural gas-fired electric generation facilities. The company was founded in 1905 and is headquartered in San Francisco, California.
VivoPower PLC
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Latest PCG
- Director Ferguson Iii Mark E gifted 10,675 shares and received a gift of 10,675 shares, decreasing direct ownership by 34% to 20,756 units (SEC Form 4)
- SEC Form 8-K filed by Pacific Gas & Electric Co.
- Director Cooper Kerry Whorton sold $20,625 worth of shares (1,250 units at $16.50) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 89,603 units (SEC Form 4)
- SEC Form 4 filed by EVP, Chief People Officer Vallejo Alejandro T
- The PG&E Corporation Foundation to Award $500,000 in Community-Focused Grants for Environmental Stewardship
- Director Cooper Kerry Whorton was granted 17,639 shares, increasing direct ownership by 24% to 90,853 units (SEC Form 4)
- Director Cannizzaro Edward G was granted 10,948 shares, increasing direct ownership by 35% to 42,427 units (SEC Form 4)
- Director Bahri Rajat was granted 10,948 shares, increasing direct ownership by 15% to 83,169 units (SEC Form 4)
- Director Campbell Cheryl F. was granted 10,948 shares, increasing direct ownership by 15% to 85,596 units (SEC Form 4)
- Director Denecour Jessica was granted 10,948 shares, increasing direct ownership by 15% to 81,715 units (SEC Form 4)
Latest VIVO
- VivoPower Appoints SpaceX Veteran Porter Harris to Support AI Data Center Power and Battery Storage Strategy
- SEC Form 6-K filed by VivoPower PLC
- VivoPower Shortlists AI Tenants for 41.5MW Norway AI Data Center After Receiving Multiple Bids
- VivoPower CIO to Address Power Access and AI Infrastructure Financing at KBRA's European Data Centers Event in London
- Presenting on Emerging Growth Conference 92 Day 2 on May 7; Register to live stream
- Presenting on Emerging Growth Conference 92 Day 1 on May 6; Register to live stream
- VivoPower to Present at the Emerging Growth Conference
- Amendment: SEC Form 6-K/A filed by VivoPower PLC
- VivoPower Targets $1.9 Million Annualized EBITDA Uplift from Enrollment of Norway Data Center into Statnett Reserve Markets Demand Response Program
- SEC Form 6-K filed by VivoPower PLC